Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan

Correction
  • 58 Downloads

1 Correction to: Pediatr Drugs 2018 20(1):97–104  https://doi.org/10.1007/s40272-017-0264-y

Page 98, Section 2.1: The following sentence, which previously read:

“Newborns, infants, or young children aged 24 months and under who have Down syndrome, and children ≤ 24 months of age without a current hs-CHD if they had experienced persistent respiratory symptoms or regular outpatient treatment due to a respiratory tract infection in previous RSV seasons were also eligible for the study.”

Should read:

“Newborns, infants, or young children aged 24 months and under who have Down syndrome (without a current hs-CHD) were also eligible for the study.”

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.AbbVie GKTokyoJapan

Personalised recommendations